Facial Injectable Market Size To Reach $24.9 Billion By 2030

Facial Injectable Market Growth & Trends

The global facial injectable market size is expected to reach USD 24.9 billion by 2030, registering a CAGR of 12.3% from 2025 to 2030, according to a new report by Grand View Research, Inc., The facial injectables are crucial in anti-aging treatments and are particularly used to stop damage such as hyperpigmentation and early aging. The most popular treatments across all socioeconomic groups are Botox and fillers, which have gained immense popularity.

Growing focus on physical appearance, especially in developing countries is one of the key factors expected to drive the market. In addition, a shift in consumer preference towards minimally invasive procedures is also expected to support market growth. According to the American Society of Plastic Surgeons (ASPS), in 2020, botulinum toxin A and soft tissue fillers were among the top 5 minimally invasive procedures carried out in the U.S. Thus, facial injectable holds high growth prospects in the years to come.

The onset of the pandemic led to nonurgent and cosmetic surgeries being put on hold in the first and second quarters of 2020. Since there were stringent restrictions imposed by the authority bodies as a precaution, the coronavirus outbreak has had an impact on every industry, including the cosmetics industry. Aesthetics-related product supply chains were also impacted. The demand-supply chain across the whole medical device sector has been severely disrupted by the pandemic.

 Request a free sample copy or view report summary: Facial Injectable Market Report

Facial Injectable Market Report Highlights

• Based on product, the botulinum toxin type A segment is projected to dominate the market throughout the forecast period. It is one of the most popularly used minimally invasive procedures

• Based on application, the facial line correction segment dominated the market and accounted for the largest revenue share of 33.2% in 2024. This growth is owing to the increasing use of facial injectables for aesthetic procedures such as facial lines, wrinkles on the face, and lip lines

• Based on end-use, the medSpa segment dominated the market and held the largest revenue share of 47.0% in 2024. All noninvasive treatments are performed in these facilities, which include facial injections, non-invasive body contouring, skin rejuvenation, and laser treatments by experienced professionals

• North America dominated the market with a revenue share of 38.9% in 2024 owing to the easy availability of the products and the presence of a large number of skilled surgeons

• The Asia Pacific region is expected to serve as a key revenue-generating center. The region is backed by countries such as India, where a growing focus on physical appearance is expected to create a lucrative opportunity for the market 

Facial Injectable Market Segmentation

Grand View Research has segmented the global facial injectable market report based on product, application, end use and region:

Facial Injectable Product Outlook (Revenue, USD Million, 2018 - 2030)

• Collagen & PMMA Microspheres

• Botulinum Toxin Type A

• HA

• CaHA

• PLLA

• Others

Facial Injectable Application Outlook (Revenue, USD Million, 2018 - 2030)

• Facial Line Correction

• Lip Augmentation

• Face Lift

• Acne Scar Treatment

• Lipoatrophy Treatment

• Others

Facial Injectable End Use Outlook (Revenue, USD Million, 2018 - 2030)

• MedSpa

• Dermatology Clinics

• Hospitals

Facial Injectable Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • Kuwait

  • UAE

List of Key Players inFacial Injectable Market

• Ispen

• Abbvie

• Medytox Inc.

• Merz GmbH and Co. KGaA

• Revance Therapeutics, Inc.

• Galderma

• Sinclair Pharma